CHST9

Across TCGA pan-cancer cohorts, CHST9 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CHST9 data layer compared with 26 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CHST9 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CHST9 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

HNSC, GBM, and LSCC are the cancer types where CHST9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.914	0.539	<.001	62	view →
GBM	DFS	Median	All	0.652	0.840	.031	1	view →
LSCC	DFS	Median	II,III,IV	0.830	1.000	.043	1	view →
LUAD	OS	Median	III,IV	0.566	1.000	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CHST9–HNSC (DFS)

Open the HNSC breakdown →